Skip to main content
glpverdict
Editorial medical reviewFDA & peer-reviewed sourcesUpdated weeklyMedically reviewed content
HomeAbout

About Glpverdict

The independent GLP-1 telehealth review portal

Glpverdict is an editorial review portal that ranks GLP-1 telehealth providers and summarises GLP-1 medications for US consumers. We are affiliate-funded, editorially independent, and medically reviewed. We do not prescribe medication, do not collect payment, and never accept pharmaceutical-company sponsorship of editorial content.

What we publish
  • Ranked provider listings β€” every GLP-1 telehealth provider scored on price, medication menu, insurance acceptance, and patient experience. Methodology is fully documented at /how-we-rank.
  • Medication profiles β€” Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, Rybelsus, and emerging agents. Each profile cites the FDA prescribing information; clinical claims trace back to peer-reviewed sources.
  • Tools + calculators β€” savings calculator, dose-escalation calendar, insurance coverage lookup, and a real-cohort outcomes tracker for opt-in users.
  • Editorial articles β€” clinical news, policy changes, side-effect deep-dives. Every YMYL article is reviewed by a named clinician listed on /authors.
Editorial team

3 named clinical contributors review our content β€” physicians, dietitians, and nurse practitioners with documented GLP-1 / obesity-medicine expertise. Each contributor has a public byline page at /authors with credentials, specialties, and review history.

Commercial model

Glpverdict earns affiliate commission when a reader clicks a tracked /go/{slug} link and completes signup with a telehealth provider. Commission size does NOT change ranking order β€” see /editorial-standards for our independence guarantee, and /refunds for how refunds work (they don't go through us). We accept no pharmaceutical-company payments of any form β€” no sponsored articles, no co-marketing, no influencer fees.

Standards we follow
  • FTC 16 CFR Β§255 β€” every affiliate CTA pairs with a clear and conspicuous material-connection disclosure.
  • FDA + YMYL β€” clinical claims cite FDA prescribing information or peer-reviewed primary sources (NEJM, JAMA, Lancet).
  • GDPR + CCPA β€” user data is processed under a documented lawful basis; data-subject requests are handled within statutory windows via /privacy.
  • WCAG 2.1 AA β€” accessibility statement at /accessibility.
  • COPPA β€” content is directed at adults 18+; minors should not submit personal data.
Business entity (operator)
Trading as
Glpverdict
Operator
Glpverdict Media LLC (US)
Founded
2024
Jurisdiction
Delaware, United States
Compliance contact
[email protected]

Affiliate-network partners requiring W-9, EIN, or DUNS verification: request via [email protected]. Operator registration details visible to network compliance officers under NDA.

Founded 2024. Last verified June 22, 2026. Contact: /contact.

About Glpverdict β€” independent GLP-1 telehealth review portal